Finance

Lists
Why is 603259 down 6,60%?
Dive Deeper
603259:SHA
WuXi AppTec Co Ltd
CNÂ¥144,30
-6,60%
(-10,20) 1D
16 Okt., 15:00:01 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603259...
Open
CNÂ¥156,94
High
CNÂ¥159,92
Low
CNÂ¥139,05
Mkt. cap
484,94 mjd
Avg. vol.
34,02 m
Volume
83,61 m
Dividend
1,45%
Quarterly dividend
CNÂ¥0,52
Ex-dividend date
04 Sep. 2026
P/E ratio
19,63
52-wk high
CNÂ¥173,60
52-wk low
CNÂ¥87,09
EPS
CNÂ¥7,35
Shares outstanding
1,05 mjd
No. of employees
36 k
Open
CNÂ¥156,94
High
CNÂ¥159,92
Low
CNÂ¥139,05
Mkt. cap
484,94 mjd
Avg. vol.
34,02 m
Volume
83,61 m
Dividend
1,45%
Quarterly dividend
CNÂ¥0,52
Ex-dividend date
04 Sep. 2026
P/E ratio
19,63
52-wk high
CNÂ¥173,60
52-wk low
CNÂ¥87,09
EPS
CNÂ¥7,35
Shares outstanding
1,05 mjd
No. of employees
36 k
News stories
From web sources and news partners
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe. Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Co Ltd
CEOSteve Yang | Ge Li
Employees35,6 k
Founded01 Des. 2000
Headquarters-
SectorHealth care
Websitewuxiapptec.com.cn
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
12,04 mjd
10,97 mjd
12,44 mjd
16,46 mjd
Cost of goods sold
6,07 mjd
4,91 mjd
6,17 mjd
-
Cost of revenue
6,07 mjd
4,91 mjd
6,17 mjd
-
Research and development expenses
311,73 m
236,94 m
266,96 m
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
854,49 m
853,67 m
891,80 m
-
Operating expense
1,38 mjd
1,26 mjd
1,22 mjd
-
Total operating expenses
7,45 mjd
6,17 mjd
7,39 mjd
-
Operating income
4,59 mjd
4,80 mjd
5,04 mjd
-
Other non operating income
-470,36 m
281,37 m
-266,37 m
-
EBT including unusual items
5,13 mjd
6,75 mjd
5,61 mjd
-
EBT excluding unusual items
5,11 mjd
6,95 mjd
5,19 mjd
-
Income tax expense
1,55 mjd
1,09 mjd
936,77 m
-
Effective tax rate
30,19%
16,12%
16,71%
-
Other operating expenses
57,96 m
25,84 m
726,05 k
-
Net income
3,51 mjd
7,08 mjd
4,65 mjd
-
Net profit margin
29,18%
64,49%
37,40%
-
Earnings per share
1,24
1,42
1,57
2,20
Interest and investment income
1,21 mjd
1,87 mjd
439,82 m
-
Interest expense
-226,71 m
-
-30,95 m
-
Net interest expenses
981,72 m
1,87 mjd
408,87 m
-
Depreciation and amortization charges
-
-
-
-
EBITDA
5,21 mjd
5,61 mjd
5,85 mjd
-
Gain or loss from assets sale
-158,03 m
218,40 m
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme